NAFLD-NASH: An Under-Recognized Epidemic

E-ISSN： 1875-6212|16|3|209-213

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.16, Iss.3, 2018-03, pp. : 209-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment

Current Vascular Pharmacology, Vol. 9, Iss. 1, 2011-01 ,pp. : 121-123

Bentham Science Publishers

Access to resources Recommend Favorite

Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk

Current Vascular Pharmacology, Vol. 16, Iss. 3, 2018-03 ,pp. : 246-253

Bentham Science Publishers

Access to resources Recommend Favorite

Clostridium difficile: an under-recognized cause of reactive arthritis?

By Birnbaum Julius Bartlett John Gelber Allan

Clinical Rheumatology, Vol. 27, Iss. 2, 2008-02 ,pp. : 253-255

Springer Publishing Company

Access to resources Recommend Favorite

Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?

Current Hypertension Reviews, Vol. 8, Iss. 4, 2012-11 ,pp. : 282-290

Bentham Science Publishers

Access to resources Recommend Favorite

The latest idea in NAFLD/NASH pathogenesis

By Ono Masafumi

Clinical Journal of Gastroenterology, Vol. 3, Iss. 6, 2010-12 ,pp. : 263-270

Springer Publishing Company

Access to resources Recommend Favorite